Loading stock data…
DNTH
$87.42-0.38 (-0.43%)
Market ClosedLast close May 1
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Dianthus Therapeutics, Inc. in the Healthcare sector is trading at $87.42. The stock is currently near its 52-week high of $96.50, remaining 86.1% above its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why DNTH maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$87.42
Potential Upside
5%
Whystock Fair Value$91.79
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Mean target$125.46+43.5%
Range$98.00 – $200.00
Fundamentals
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.97B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-23.26%
Volume
Today's trading volume
471,427
Recent News
Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Trial Shift And Renewed Analyst Optimism
The FDA’s decision to relax certain safety screening and testing requirements for claseprubart trials, alongside William Blair’s reaffirmed positive view, has put Dianthus Therapeutics (DNTH) squarely in focus for biotech investors. See our latest analysis for Dianthus Therapeutics. Despite a 2.7% one day share price decline and a 4.9% 7 day share price pullback to US$87.39, Dianthus still shows a 7.7% 1 month share price return, a 73.7% 3 month share price return and a very large 1 year...
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier
Dianthus Therapeutics Inc (NASDAQ:DNTH) is among the best 52-week high US stocks to buy. On March 26, William Blair reaffirmed an Outperform rating on Dianthus Therapeutics Inc (NASDAQ:DNTH) stock. This action followed an FDA update on safety requirements for Dianthus Therapeutics’ claseprubart clinical trials. In the safety update, the FDA has dropped antinuclear antibodies as […]
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
This clinical-stage biotech focused on monoclonal antibody therapies reported a notable insider sale in its latest SEC filing.
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
This biotech firm developing antibody therapies for rare diseases disclosed a significant insider sale amid rapid share price gains.
How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For Claseprubart
Dianthus Therapeutics recently reported an early “GO” decision for its late-stage CAPTIVATE study of claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), after meeting interim responder goals ahead of schedule. At the same time, the FDA agreed to broaden clinical development changes for claseprubart, covering screening, lab work, and autoimmune safety monitoring, across all current and future studies, potentially simplifying the path for this program. With claseprubart’s...